MDWD News and Press, MediWound Ltd. From 11/14/19

MediWound (NASDAQ: MDWD ): Q3 GAAP EPS of -$0.11 beats by $0.04 . More news on: MediWound Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Total revenues of $5.1 million, driven primarily by revenues from development services Initiated U.S. NexoBrid expanded access treatment (NEXT) protocol, with plans on track for NexoBrid® BLA filing in the second quarter of 2020 Expected to initiate patient treatment in Escha...

YAVNE, Israel, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the ...

CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) and MediWound Ltd. (NASDAQ: MDWD) today announced initiation of the NexoBrid ® expanded access treatment protocol (NEXT) to treat burn patients with deep partial- and full-thicknes...

YAVNE, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound care management, today announced a significant presence at the 18 th European Burns As...

MediWound Ltd. (MDWD) Q2 2019 Results Earnings Conference Call August 13, 2019 08:30 AM ET Company Participants Monique Kosse - LifeSci Advisors Sharon Malka - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Anthony Petrone - ...

MediWound (NASDAQ: MDWD ): Q2 Non-GAAP EPS of -$0.12 misses by $0.09 ; GAAP EPS of $0.47 beats by $0.50 . More news on: MediWound Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Total revenues of $20.7 million, driven primarily by the upfront payment from Vericel for NexoBrid ® license agreement BARDA committed additional $21 million to fund NexoBrid ® expanded access treatment protocol Confirmed BLA submission plans in a pre-BLA meeting with...

YAVNE, Israel, Aug. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the ...

Gainers: Allakos (NASDAQ: ALLK ) +129% . MediWound (NASDAQ: MDWD ) +15% . Four Seasons Education (Cayman) (NYSE: FEDU ) +12%  KemPharm (NASDAQ: KMPH ) +12% .  Sandstorm Gold (NYSEMKT: SAND ) +11% . Endeavour Silver (NYSE: EXK ) +10% . MoneyGram International (NASDAQ: MGI )...